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Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder in children that is charac-
terized by persistent fever, splenomegaly with cytopenia, hypertriglyceridemia, and hypo-
fibrinogenemia. Increased levels of various cytokines and soluble interleukin-2 receptor 
are biological markers of HLH. HLH can be classified into two major forms: primary and 
secondary. Familial hemophagocytic lymphohistiocytosis (FHL), a type of primary HLH, 
is an autosomal recessive disorder that typically occurs in infancy and can be classified 
into five different subtypes (FHL types 1–5). In Japan, >80% of patients with FHL have 
either PRF1 (FHL type 2) or UNC13D (FHL type 3) defects. FHL is considered to be a 
disorder of T-cell function because the activity of NK cells or cytotoxic T lymphocytes as 
target cells is usually impaired. Moreover, Epstein–Barr virus-associated HLH (EBV-HLH) 
is considered a major subtype of secondary HLH. Any genetic background could have 
an effect on the pathogenesis of secondary HLH because EBV-HLH is considered to 
be particularly prevalent in Asian countries. For primary HLH, hematopoietic stem cell 
transplantation is the only accepted curative therapy, although cord blood transplanta-
tion with a reduced-conditioning regimen has been used with superior outcomes. For 
secondary HLH, including EBV-HLH, immunochemotherapy based on the HLH-2004 
protocol has been used. In the near future, the entire mechanism of HLH should be clar-
ified to establish less toxic therapies, including cell therapy and gene targeting therapy.
Keywords: hemophagocytic lymphohistiocytosis, familial, epstein–Barr virus, genetic defects, cytotoxicity, 
hematopoietic stem cell transplantation
iNTRODUCTiON
Hemophagocytic lymphohistiocytosis (HLH) in children is characterized by persistent fever, 
splenomegaly with cytopenia, hypertriglyceridemia, and hypofibrinogenemia. The infiltration of 
histiocytes with hemophagocytic activity is usually observed in reticuloendothelial systems, includ-
ing the bone marrow (BM) and central nervous system (CNS) (1). HLH is classified into two major 
forms: primary and secondary. Primary HLH includes familial hemophagocytic lymphohistiocytosis 
(FHL) and several primary imunodeficiencies, which exhibit genetic inheritance and usually occur 
in infancy. Secondary HLH is associated with infections [mainly Epstein–Barr virus (EBV)], auto-
immune disorders (mainly juvenile idiopathic arthritis), or malignancies (mainly non-Hodgkin’s 
lymphoma) (2). The pathogenesis of HLH has been recently clarified to be the impaired activation 
of T lymphocytes following stimulation by immune responses, resulting in large quantities of inflam-
matory cytokines that promote macrophage infiltration and cytokine network formation (3).
TABLe 1 | Diagnostic criteria of HLH.
1. Only for primary HLH
Defects of known causable genes
Positive family history
2. Clinical findings
Fever
Splenomegaly
Cytopenia: Hb <9.0 g/dl, platelets <100,000/μl, and neutrophils <1,000/μl
Hypertriglyceridemia and/or hypofibrinogenemia
High triglycerides >3.0 mmol/l
Low fibrinogen <150 mg/dl
Hemophagocytosis
3. Laboratory findings
Low NK cell activity
Hyperferritinemia (>500 ng/ml)
High sIL-2R (>2,400 U/ml)
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Several genetic defects in primary HLH, particularly FHL, 
have been recently identified, which include perforin (PRF1), 
Munc13-4 (UNC13D), syntaxin 11 (STX11), and Munc18-2 
(STXBP2) (4–7). In Japan, 80% of patients with FHL have either 
PRF1 or UNC13D defects, whereas >10% have unknown genetic 
defects, which should be elucidated in the future (8). Although 
primary HLH can be controlled by immunochemotherapy, 
hematopoietic stem cell transplantation (HSCT) is required as 
a curative therapy. Furthermore, the outcome of EBV-HLH has 
been superior with immunochemotherapy on the basis of the 
HLH-94/HLH-2004 protocol. However, some patients who are 
resistant to conventional therapy also require HSCT.
This review focuses on the recent advances of analysis regard-
ing pathogenesis and treatment of HLH. Identifying all mecha-
nisms underlying HLH could facilitate the development of novel 
approaches, including cell therapy and gene targeting therapy, in 
the future.
CLiNiCAL AND LABORATORY  
FiNDiNGS OF HLH
The clinical findings of HLH are usually non-specific, as other 
disorders including severe infections or secondary HLH in 
infancy display similar clinical findings. The important criteria 
to diagnose initially as HLH that was proposed by the HLH-2004 
study include persistent fever that is resistant to antibiotics and 
splenomegaly with or without hepatomegaly (Table  1) (9). As 
other findings, pulmonary infiltrates and pleural effusion were 
described in a few patients (3). Neurological abnormalities 
including irritability, depressed consciousness level, hypotonia, 
and convulsions can be seen especially in FHL. These neurological 
abnormalities are associated with CNS infiltration of histiocytes 
or lymphoid cells with hemophagocytic activity (3). Additional 
symptoms including icterus, ascites, and edema are frequently 
observed late in the course of HLH.
Laboratory findings include cytopenia (affecting ≥2 of 
three lineages in the peripheral blood), hypertriglyceridemia 
and/or hypofibrinogenemia, liver dysfunction with high 
LDH, hyperferritinemia, and hemophagocytosis in BM or 
the reticuloendothelial system (spleen and lymph nodes) (3). 
Leukocyte count at diagnosis varies among patients, whereas the 
majority of patients exhibit anemia and/or thrombocytopenia 
(1). Without treatment, nearly all patients develop severe pan-
cytopenia with progression of the disease, which necessitates 
frequent transfusions (1, 3). Compared with secondary HLH, 
hemophagocytosis in BM can detected in only half or two-thirds 
and repeated BM examinations are necessary for the diagnosis 
of FHL (3). Pleocytosis with an increased protein level in the 
cerebrospinal fluid or abnormal radiological findings of the brain 
that were detected using CT or MRI can be sometimes observed 
at onset or during the course of the disease, despite the absence of 
neurological abnormalities. Among them, hypertriglyceridemia 
and/or hypofibrinogenemia and hyperferritinemia are diagnos-
tic criteria for HLH (Table 1) (9).
Various serum cytokines and chemokines have been used 
as biological markers of HLH (10). In particular, the levels of 
tumor necrosis factor (TNF)-α and interleukin (IL)-6, which are 
secreted by activated monocytes/macrophages, and interferon-γ 
and soluble CD8 antigens, which are secreted by T lymphocytes, 
are increased in patients with HLH. The level of soluble IL-2 
receptor sCD25 is elevated in patients with HLH, suggesting the 
activation of T lymphocytes in this disorder. Low or deficient 
NK cell activity is observed in the majority of patients with FHL, 
whereas low NK activity occurs in some patients with secondary 
HLH, which usually returns to normal following treatment (11). 
Increased soluble IL-2 receptor levels and low or deficient NK 
activities can serve as diagnostic markers of patients with HLH 
(Table 1).
MeCHANiSM OF NK/CTL-MeDiATeD 
CYTOTOXiCiTY
NK/CTL-mediated cytotoxicity plays a central role in the patho-
genesis of HLH. Various pathways, including perforin/granzymes, 
Fas/Fas ligand, membrane-bound TNF-α, membrane-bound lym-
photoxin, and TNF-related apoptosis-inducing ligand (TRAIL), 
have been implicated in NK/CTL-mediated cytotoxicity (12). 
Among these, two pathways, exocytosis of lytic granules medi-
ated by perforin/granzyme and Fas/Fas ligand interactions, have 
been identified as the main mechanisms of NK/CTL-mediated 
antigen-specific cytotoxicity (Figure  1) (13, 14). In particular, 
the former pathway involves pore formation in the target cell 
membrane through extracellular Ca2+-dependent polymeriza-
tion of perforin, which is accompanied by the release of serine 
proteases, granzymes, which are responsible for the downstream 
activation of caspase-3 and subsequent DNA fragmentation, 
resulting in target-cell apoptosis (3). The genetic defects in FHL 
and several primary immunodeficiencies have been identified to 
code the molecules involved in the perforin/granzyme pathway. 
In fact, our preliminary studies demonstrated that using CD4+ 
and CD8+ CTLs, the perforin/granzyme-dependent cytotoxic 
pathway is impaired in patients with FHL (15, 16).
The molecular mechanism underlying the perforin/granzyme 
pathway is shown in Figure 2 (17). Perforin and granzyme are 
included in lytic granules of NK/CTLs. The final step of granule 
FiGURe 2 | Secretion of lytic granules in NK/CTL. After stimulating target 
cells, CTL organizes the immunological synapse. Rab27a promotes the 
transporting and docking of lytic granules at the immunological synapse 
along with Munc13-4. Interactions between Munc18-2 and SNARE (such as 
syntaxin 11) allow lytic granules to reach the synapse, where granule 
secretion occurs.
FiGURe 1 | Mechanisms of CTL-mediated cytotoxicity. Various pathways, including perforin/granzyme, Fas/Fas ligand, membrane-bound TNF-α, membrane-
bound lymphotoxin, and TRAIL, underlie CTL-mediated cytotoxicity. Among these, granule exocytosis that is mediated by the perforin/granzyme and Fas/Fas ligand 
pathways are believed to be the main mechanisms of CTL-mediated antigen-specific cytotoxicity.
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transportation is mediated by the immunological synapse between 
granules and their target membrane through the formation of a 
complex between a vesicle-SNARE (v-SNARE) protein, such as 
a VAMP, and a target membrane-SNARE (t-SNARE), such as a 
syntaxin11 or a member of SNAP23/25/29 (8, 18). The SNARE 
complex comprises three molecules: VAMP, syntaxin11, and 
SNAP23/25/29. However, the precise biological functions of 
the SNARE system remain poorly understood. Recent evidence 
suggests that members of the SNARE family mediate the fusion 
of cytotoxic lytic granules with the surface of CTLs. Syntaxin11, 
SNAP23, and VAMP7 are prime candidates that function as 
SNAREs in this fusion event (19).
GeNeTiC DeFeCTS AND  
PATHOGeNeSiS OF FHL
Genetic defects responsible for FHL have been identified by vari-
ous methods. Linkage analysis has indicated one possible locus of 
FHL type 1 at 9q21.3–22; however, a causative gene remains to be 
identified (20). In 1999, a mutation in the perforin gene (PRF1) 
was identified as the cause of FHL type 2 (4). Thereafter, genetic 
mutations of the Munc13-4 gene (UNC13D) as a cause of FHL 
type 3, syntaxin11 gene (STX11) as a cause of FHL type 4, and 
Munc18-2 gene (STXBP2) as a cause of FHL type 5 were identi-
fied (5–7). These mutations affect the proteins that are involved in 
the transportation, membrane fusion, or exocytosis of perforin/
granzyme of the lytic granules of NK/CTLs.
The incidence of each subtype varies among countries. Our 
recent study demonstrated that the actual incidences of FHL 
types 2 and 3 in Japan were approximately 55 and 32%, respec-
tively, whereas FHL type 5 accounted for only 6%, with no cases of 
FHL type 4 having yet been reported (8). It is notable that in some 
cases of FHL, the responsible genetic mutation is unknown. In 
West Asian countries, mutations of three genes (PRF1, UNC13D, 
and STX11) were identified in 80% of patients with FHL, while 
STXBP2 mutation accounted for only 10% (21). In contrast, in 
Korea, most patients with FHL had UNC13D mutations (22). In 
North America, the incidence of a PRF1 mutation is the highest, 
FiGURe 3 | Correlation among genetic subtype, CTL activity, and age at onset of FHL. The cytotoxicity of CD8+ T-cell lines that were generated from 
patients with different FHL subtypes was determined. Cytotoxicity was deficient in patients with FHL2 having PRF1 nonsense mutations and was very low in patients 
with FHL3 having UNC13D nonsense mutations but was moderate in those with missense mutations.
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followed by UNC13D and STXBP2 (23). Thus, the distribution of 
each FHL subtype varies among different ethnic groups.
In the SNARE system, perforin is critical for granzyme delivery 
and Munc13-4 is essential for priming of cytotoxic granules that 
are docked at the immunological synapse, whereas syntaxin11 
regulates membrane fusion events (8, 24, 25). Via the interac-
tion with syntaxins11, Munc18-2 is required for docking and the 
fusion of lytic granules with the immunological synapse (26). 
A recent report indicated that docked granules are primed for 
fusion by Munc13-4 when Munc18-2 clasps across the zippering 
4-helix-assembled trans-SNARE complex (27). These findings 
suggest that at the immunological synapse, the Munc18-2/syn-
taxin11/Munc13-4 complex may play a role by regulating granule 
docking and initiating SNARE formation prior to the priming 
step (8, 24, 25). These findings support the hypothesis that the 
cytotoxic activities of NK/CTLs in FHL types 3–5 are impaired 
to a similar degree.
FHL typically occurs within the first year of life in 70–80% of 
cases, whereas late-onset cases and teenagers with PRF1 defects 
have also been described and all had a missense mutation at 
least in one allele (28). NK cell function was also impaired in 
the majority of these cases. We analyzed the relationships among 
genetic defects, CTL activities, and ages at the onset of different 
FHL subtypes and found that CTL-mediated cytotoxicity was 
deficient in patients with FHL2 having a PRF1 nonsense muta-
tion and onset was usually in early infancy, while cytotoxicity 
was low in patients with FHL3 having an UNC13D nonsense 
mutation and onset also occurred in infancy (Figure  3) (16). 
However, cases with a genetic missense mutation were associated 
with moderate CTL-mediated cytotoxicity and the onset was 
after the age of >1 year, indicating the close association between 
the type of genetic mutation, degree of CTL cytotoxicity, and age 
at onset. A few patients with a PRF1 missense mutation have 
survived without undergoing HSCT.
HLH iN PRiMARY iMMUNODeFiCieNCieS
HLH develops in various primary immunodeficiencies, includ-
ing Chediak–Higashi syndrome (CHS), Griscelli syndrome (GS) 
type 2, Hermansky–Pudlak syndrome (HPS) type 2, and X-linked 
lymphoproliferative disease (Table 2). Although FHL is most com-
mon, these hereditary diseases should be a differential diagnosis 
of primary HLH. Affected organs are important to distinguish 
these hereditary diseases. The combination of immunodeficiency 
and albinism of the skin or hair are observed in CHS, GS type 2, 
and HPS type 2, but not in FHL.
Among these immunodeficiencies, only patients with CHS 
have been reported in the registry system of Japan, while the 
number of CHS cases has been only one per year. A mutation 
of the lysosomal trafficking regulator (LYST) gene at 1q42–44 
is the cause of CHS. LYST encodes a cytoplasmic protein 
that modulates lysosomal exocytosis (29). The LYST protein 
interacts with some cytoplasmic proteins, such as hepatocyte 
growth factor-regulated tyrosine kinase substrate (HRS), 
casein kinase II, calmodulin (CALM), and 14-3-3 proteins, 
forming a complex that plays an important role in regulating 
the vesicular transport and signal transduction. HRS inhibits 
exocytosis by binding SNAP25, a component of the SNARE 
protein complex that is important in vesicle docking and 
fusion (30). The LYST protein binds to HRS, forming the 
HRS–LYST complex, which is unable to bind SNAP25. In 
CHS, the absence of LYST might prevent juxtaposition of HRS 
and CALM, thereby potentiating HRS inhibition of SNAP25 
and inhibiting membrane docking and fusion (30). The LYST 
defect causes neutrophil digestion and migration and NK/
CTL cytotoxicity.
Most patients with CHS develop HLH as an “accelerated phase” 
during infancy or childhood, whereas some patients exhibit a 
mild phenotype and survive to adulthood without HLH. A recent 
TABLe 2 | Gene mutations associated with primary HLH.
Chromosome Gene Protein and/or function
FHL
FHL 1 9q21.3–22 Unknown Unknown
FHL 2 10q22 PRF1 Perforin: apoptosis and cytotoxicity
FHL 3 17q25.1 UNC13D Munc13-4: exocytosis of granules
FHL 4 6q24 STX11 Generation of granules with SNAP23
FHL 5 19p13.3–2 STXBP2 Syntaxin-binding protein 2
XLP
XLP1 Xq25 SH2D1A SAP: activation of lymphocytes
XLP2 Xq25 XIAP XIAP: inhibitor of apoptosis
Griscelli syn II 15q21 RAB27A Exocytosis of granules
Hermansky–Pudlak syn II 5q14.1 AP3B1 AP3βchain: traffic from Golgi to granules
Chediak–Higashi syn 1q42.1–2 LYST Transport of lysozome
ADA deficiency 20q13.11 ADA Metabolism of nucleic acids
PHP deficiency 14q13.1 PNP Metabolism of nucleic acids
IL-2Rα chain def. 10p15–14 IL-2RA IL-2R: T cell activation and regulation
Common γ chain def. Xq13 IL-2RG IL-2R: T cell activation and regulation
Wiskott–Aldrich syn Xp11.23–22 WASP WASP: cytoskeleton
DiGeorge syn 22q11.2 DCGR Unknown/various
XL-O-EDA-ID X28 NEMO NEMO protein
XLA Xq21.3-q22 BTK B cell maturation and proliferation
Hyper-lgD syn 12q24 MVK Mevalonate kinase
Lysinuric pro. intolerance 14q11.2 SLC7A7 Transport of amino acid
Multiple sulfatase def. 3p26 SUMF1 FGE: transcriptional activation of sulfatase
Cobalamin C disease 1p MMACHC Metabolism of vitamin B12
Hott–Oram syn 12q24.1 TBX5 promotes cardiomyocyte differentiation
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study reported that cytotoxic function was  significantly reduced in 
patients with CHS who developed early onset HLH (31). Recently, 
we analyzed 15 patients with CHS in Japan, of whom 5 (33%) 
developed life-threatening HLH (32). Five patients, including 
3 with HLH, underwent HSCT, and 10 patients survived. LYST 
analysis was performed in nine cases, which identified six dif-
ferent mutations in six patients, while no mutation was found in 
the remaining three patients. CTL cytotoxicity was particularly 
impaired in patients who developed HLH. Thus, patients with low 
CTL cytotoxicity can develop HLH during the course of a disease.
ePSTeiN–BARR viRUS-ASSOCiATeD 
HeMOPHAGOCYTiC 
LYMPHOHiSTiOCYTOSiS
EBV-HLH is a major subtype of secondary HLH that is induced 
by a primary EBV infection. In a nationwide survey, the most 
frequent subtype in Japan is EBV-HLH (approximately 40% of all 
patients with HLH), followed by other infection- or lymphoma-
associated HLH (2). EBV-HLH, an EBV infection, will exclusively 
occur in T and/or NK cells (33). The incidence of EBV-HLH is 
relatively high in Asian countries, indicating the underlying 
genetic background in the pathogenesis of EBV-HLH.
The exact mechanism underlying EBV induction of HLH has 
been elucidated. A previous report suggested that EBV-infected 
B cells induce the proliferation of cytotoxic T cells followed by 
the activation of macrophages, resulting in uncontrolled immune 
activation and induced hypercytokinemia, which is known as a 
“cytokine storm” (34). Another report suggested that EBV targets 
CD8+ T or NK cells via CD21, which is expressed on the surface 
of these cells, leading to uncontrolled production of cytokines 
because of widespread lymphohistiocytic activation (35).
Phenotypically, EBV-HLH is a heterogeneous disorder with 
various symptoms, ranging from mild to severe, and with a 
variable clinical course, ranging from self-limiting to severe/
aggressive or fatal. Therefore, prompt and appropriate treatment 
should be established according to prognostic factors, which will 
be addressed later.
T-cell receptor (TCR) gene rearrangement is detectable in 
half of the patients with EBV-HLH using Southern blotting and/
or PCR analyses. We speculate that the presence and change of 
TCR gene clonality is likely to be associated with the outcome of 
patients with EBV-HLH. Sandberg et al. (36) recently reported 
that BIOMED-2 multiplex PCR could replace Southern blot 
analysis in routine testing of T-cell clonality. We also analyzed 
TCR gene clonality with BIOMED-2 multiplex PCR in six 
patients with EBV-HLH (37). All patients showed monoclonal 
peaks in TCRβ and/or TCRγ at diagnosis, and serial monitoring 
of one patient disclosed a change in the rearrangement pattern 
of the TCR genes in response to immunochemotherapy, indicat-
ing that BIOMED-2 multiplex PCR, a highly sensitive method 
for detecting T-cell clonality, is useful to predict the therapeutic 
response of patients with EBV-HLH (37).
FiGURe 4 | Outcome of neonatal HLH with different subtypes. The 
5-year overall survival rate of neonates with primary HLH (FHL and 
SCID-HLH) and HSV-HLH was poor compared with those with other HLH 
subtypes, although no significant difference was observed among the three 
groups. Adapted from Suzuki et al. (38). Permission granted by Elsevier.
FiGURe 5 | Survival of patients with eBv-HLH. Outcome of patients with 
EBV-HLH having both hyperbilirubinemia and hyperferritinemia at diagnosis 
was significantly poorer than for those having low bilirubin and ferritin levels. 
Adapted from Kogawa et al. (44). Permission granted by John Wiley and 
Sons.
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NeONATAL HLH AND HeRPeS  
SiMPLeX viRUS
Neonatal HLH onset within 4 weeks after birth is very rare, and 
the diagnosis is frequently delayed, made at autopsy, or some-
times not made because of the lack of recognition of the disease. 
Neonatal HLH can be distinguished from HLH in older children 
with respect to etiology, manifestations, and laboratory findings. 
Of 20 neonates (10 males and 10 females) who were diagnosed 
with HLH within 4  weeks after birth, 6 (30%) were diagnosed 
with FHL and 6 (30%) were diagnosed with herpes simplex 
virus-associated HLH (HSV-HLH) (38). The overall survival 
rate of these 20 patients was 40:28.6% for FHL and SCID-HLH 
and 33.3% for HSV-HLH, despite the use of acyclovir-containing 
therapies (Figure 4).
Although HSV or enterovirus are not common pathogens in 
HLH of older children, fatal or fulminant enterovirus (echovirus 
and coxsackievirus) and HSV infections sometimes exasperate 
HLH in neonates (39, 40). Hence, prompt administration of high-
dose acyclovir for neonatal HLH before diagnosis by viral studies 
should be mandatory.
TReATMeNT OF HLH
Today, effective initial therapy of HLH consists of combinations 
of proapoptotic chemotherapy and immunosuppressive drugs 
targeting the hyperactivated T cells and histiocytes (41). Most of 
the HLH patients have severe systemic symptoms at diagnosis, 
and timely appropriate treatment for HLH is needed before 
genetic testing to distinguish primary from secondary HLH. 
Early use of γ-globulin and/or corticosteroid is sometimes useful 
to control the activity of HLH, with transient effect (1). However, 
an aggressive therapeutic approach is warranted in most cases, 
including immunochemotherapy and HSCT.
The HLH-94 and HLH-2004 studies were both mainly 
 organized for treating primary HLH by HSCT. The first trial 
HLH-94 study included dexamethasone, cyclosporine A, and 
etoposide for 8-week-induction therapy, followed by HSCT in 
patients with familial, persistent, or recurrent disease (42). The 
results were reported elsewhere (43). The 5-year survival rate was 
54 ± 6% in all patients, and 66 ± 8% in those undergoing HSCT. 
Notably, 72 patients (29%) died during the first 2 months before 
HSCT, mostly because of disease reactivation, particularly pro-
gression of CNS disease (43). The second trial HLH-2004 study 
also included dexamethasone, cyclosporine A, and etoposide; 
compared with HLH-94 study, cyclosporine A was used at the 
onset of disease in HLH-2004 study, and intrathecal therapy with 
methotrexate and corticosteroids was added in selected patients 
(9). Although the treatment results have not been still published, 
the number of patients who died during the first 2 months before 
HSCT has been reduced compared that of HLH-94 study.
Most of the patients with secondary HLH including EBV-
HLH have been registered and treated according to the HLH-94 
or HLH-2004 studies. In our recent analysis, more than half of 
the patients with EBV-HLH were treated with immunochemo-
therapy based on the HLH-94/HLH-2004 protocol, while 30% 
were treated with a corticosteroid-based therapy and 10% with 
only supportive therapy, resulting in complete remission in 90% 
of patients following initial therapy. In these patients, recur-
rence was observed in only 8.3% and remission was achieved 
again with additional therapy (44). Among several prognostic 
factors, patients with both hyperbilirubinemia (>1.8  mg/dl) 
and hyperferritinemia (>20,300 ng/ml) at the time of diagnosis 
had significantly poorer outcomes than those with low serum 
bilirubin and ferritin levels (Figure  5) (44). The presence and 
change of T-cell clonality are also good markers to predict treat-
ment response, as described above. EBV-HLH is a heterogeneous 
disorder with various symptoms and clinical courses. Therefore, 
we recommend initial treatment with high-dose γ-globulin and/
or corticosteroid therapy for all patients with EBV-HLH, followed 
TABLe 3 | Profiles of survived and died FHL patients.
Survived (n = 29) Died (n = 14) p-value
Males/females 13:16 10:4 ns
Age at onset (mean, range) 0.6 (0.1–12 years) 0.3 (0.1–0.8 years) ns
FHL2:FHL3 7:5 5:3 ns
Manifestation at diagnosis (%)
Fever 96 (27/28) 93 (13/14) ns
Hepatosplenomegaly 82 (23/25) 93 (13/14) ns
Lymphadenopathy 29 (8/28) 7 (1/14) ns
Skin eruption 21 (6/28) 0 (0/14) ns
CNS abnormality 21 (6/28) 21 (3/14) ns
Respiratory failure 14 (4/28) 14 (2/14) ns
DIC 25 (7/28) 50 (7/14) ns
CNS signs at HSCT (%) 68 (19/28) 64 (9/14) ns
CSF pleocytosis 44 (7/16) 0 (0/6) ns
MRI abnormality 52 (13/25) 50 (7/14) ns
Convulsion 37 (10/27) 80 (7/14) ns
Disturbed consciousness 26 (7/27) 21 (3/14) ns
HSCT
Age at HSCT (mean, range) 1.7 (0.4–15 years) 1.1 (0.7–4.8 years) ns
UGBT:others 11:6 6:7 ns
MAC:RIC 20:7 9:5 ns
CNS, central nerves system; HSCT, hematopoietic stem cell transplantation; CSF, cerebrospinal fluid; UCBT, unrelated cord blood transplantation; MAC, myeloabrative conditioning; 
RIC, reduced-intensity conditioning; ns, not significant.
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by immunochemotherapy for those resistant to initial therapy or 
with several risk factors. HSCT is also optional for relapsed cases. 
Recent experience suggests that reduced-intensity conditioning 
(RIC) regimes can improve the outcome of patients with HLH 
undergoing allogeneic HSCT, despite a significant incidence of 
mixed chimerism (45, 46).
In Japan, 57 patients (43 with FHL and 14 with EBV-HLH) 
underwent HSCT between 1995 and 2005 (47). Unrelated 
donor cord blood transplantation (UCBT) was employed in half 
of these cases and RIC regimen was used in 26%. The overall 
survival rate was 65.0% for FHL and 85.7% for EBV-HLH. 
Prognosis was better for EBV-HLH than for FHL after HSCT 
because of the high incidence of early treatment-related deaths 
in FHL. We compared the profiles of patients with FHL who 
survived with those who died and found no significant differ-
ences (Table 3) (47). The survival rate of patients undergoing 
UCBT with RIC was almost comparable with that of those 
undergoing other transplantation or myeloablative condition-
ing. Therefore, UCBT with RIC might be acceptable as optimal 
HSCT for FHL. Considering the high frequency of rejection 
in UCBT, the use of high-dose melphalan (≥120 mg/m2) and 
additional modifications, including antithymocyte globulin 
(ATG) or low-dose total-body irradiation, may be required to 
attain a stable chimera (48).
The effectiveness of the addition of rituximab to the initial 
treatment in the HLH-2004 study was recently reported in the 
US (49). Because EBV initially infects B cells, rituximab is con-
sidered effective as an early treatment for EBV-HLH. Moreover, a 
recent report suggested that B cells may also be targeted in EBV-
associated disease; thus, directed therapy with rituximab may 
reduce the morbidity and mortality by reducing the population 
of circulating B cell and EBV load. ATG-based immunotherapy 
of FHL has also been reported to be successful with an acceptable 
toxicity when used as a first treatment of familial HLH (50). The 
use of ATG to target EBV-infected T cells may merit investigative 
trial in the near future.
The other salvage therapies have not established for refractory 
HLH. Recently, based on the critical role of T cells in HLH patho-
genesis, Alemtuzumab, a monoclonal antibody to CD52, had 
significant response against refractory HLH (23, 51). However, 
CMV reactivation and adenoviremia were frequent complica-
tions of this therapy. The effect of ATG is still controversial for 
refractory HLH and accumulation of patients who will be treated 
with ATG in the future.
Supportive care is important during the course of treatment 
for HLH which includes the prophylaxis of Pneumocystis jirovecii, 
fungal, or oppotunistic infection, and empiric broad-spectrum 
antibiotics or antifungal therapy should be initiated (23). To 
increase neutrophil counts, granulocyte-colony stimulating fac-
tor (G-CSF) can be also used for myelosuppression.
FUTURe DiReCTiONS
In HLH, appropriate diagnosis and prompt treatment according 
to each subtype are necessary. To date, there is limited evidence 
of any major advantage of prompt HSCT with regard to the 
survival of patients with HLH. The HLH-2004 study recom-
mends HSCT only for familial disease or severe and persistent 
non-familial disease. Early identification of genetic defects and 
impaired NK/CTL cytotoxicity may also support the use of the 
HLH-2004 protocol for primary HLH. After identifying genetic 
abnormalities in FHL, the association among phenotypes, 
genotypes, and cytotoxic functions of CTLs will be helpful in 
establishing appropriate timings of HSCT. In patients in whom 
no genetic defect can be identified, samples should be used for 
identifying unknown genes that are responsible for other FHL 
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